TheBrief.Health

Real-world data show about one-quarter of lupus patients achieve six-month remission with anifrolumab, supporting earlier targeted therapy, steroid reduction, and evolving care pathways for systemic lupus erythematosus.

Research links sleep disruption to microglial activation, reframing insomnia as neuro-immune stress that may drive inflammation, cognitive fog, mood symptoms, and long-term brain vulnerability.

Long-term data from the ACTIVE trial suggest speed-based cognitive training with boosters may lower dementia risk, supporting scalable, nonpharmacologic prevention strategies for at-risk older adults.

FDA grants accelerated first-line approval to zongertinib, a selective oral HER2 TKI, redefining treatment for HER2-mutant metastatic NSCLC with high response rates and precision-first strategy.

FDA-cleared CTA software creates patient-specific 3D cardiac conduction maps for planning and live guidance, aiming to reduce conduction injury, pacing complications, and procedural uncertainty.

Gut microbiota and IgA shape vaccine effectiveness. Disrupted mucosal immunity may reduce response, guiding clinicians to evaluate nonresponse, personalize vaccination, and protect vulnerable populations.

Patient-centered integration of spirituality into substance use care can enhance prevention and recovery, provided boundaries, autonomy, and evidence-based treatments remain central to clinical decision making.

Emerging evidence links sleep disruption to microglial activation, connecting fragmented sleep with inflammation, cognitive impairment, mood symptoms, and potential long-term neurodegenerative vulnerability, reframing insomnia as neuro-immune stress.

COVID-19 mRNA vaccination near immunotherapy initiation may enhance cancer survival by reprogramming tumor immunity, potentially transforming “cold” tumors and reshaping oncology practice, policy, and research priorities.

Rising rheumatology article retractions, largely driven by misconduct, threaten evidence integrity, clinical decision making, patient safety, and trust in research guiding lifelong autoimmune disease treatment.

Off-label therapies for alopecia areata expand options beyond approved treatments, balancing access, safety, monitoring, and equity while evidence gaps complicate shared decision making and long-term outcomes.

Administrative barriers and benefit design delays in metabolic care restrict access to GLP-1 and incretin therapies, worsening diabetes and obesity outcomes while widening equity gaps.

Healthy aging prioritizes function, independence, and dignity through routine functional assessment, deprescribing, fall prevention, sensory support, caregiver engagement, and team-based, community-connected care aligned with patient goals.

Long-term data show some irritable bowel syndrome patients later develop inflammatory bowel disease, underscoring risk-stratified follow-up, red flag recognition, and targeted testing to prevent delayed diagnosis.

Acute optic neuritis demands rapid escalation to plasma exchange in high-risk or steroid-refractory patients, preserving vision by removing pathogenic antibodies before irreversible optic nerve damage occurs.

In suspected metastatic breast cancer, tissue biopsy confirms diagnosis, updates receptor status, guides targeted therapy, prevents misclassification, enables trial access, and supports timely, personalized treatment decisions.

A new biopsychosocial risk score predicts persistent, widespread, or high-impact chronic pain, enabling earlier personalized care, safer prescribing, and better health system planning for vulnerable patients.

Emerging evidence suggests menopausal hormone therapy enhances tirzepatide-driven weight loss in postmenopausal women, offering a synergistic, hormone-informed approach to obesity, metabolic risk reduction, and healthier aging.

Polycystic ovary syndrome requires individualized, stepwise care addressing menstrual irregularity, androgen symptoms, fertility goals, metabolic risk, and mental health through long-term, coordinated multidisciplinary management.

A large Swedish study finds COVID-19 vaccination does not reduce fertility or childbirth rates, providing strong evidence to counter misinformation and reassure women and healthcare providers worldwide.

Early-life exposure to air pollution and household dampness increases childhood asthma risk by altering lung development and immunity, highlighting urgent needs for cleaner air and healthier housing.

A large study finds U.S. mothers experience persistent postpartum depression without recovery, highlighting systemic failures in paid leave, childcare, and healthcare compared with the UK and Australia.

Rotavirus infection triggers sweeping mRNA and lncRNA transcriptomic shifts in MA104 cells, reshaping immune and metabolic pathways and revealing novel molecular targets for vaccines and antiviral therapies.

Rotavirus infection triggers sweeping mRNA and lncRNA transcriptomic shifts in MA104 cells, reshaping immune and metabolic pathways and revealing novel molecular targets for vaccines and antiviral therapies.